Covalent Inhibition of HIV-1 Integrase by N-Succinimidyl Peptides

ChemMedChem. 2016 Sep 20;11(18):1987-94. doi: 10.1002/cmdc.201600190. Epub 2016 Jun 22.

Abstract

We present a new approach for the covalent inhibition of HIV-1 integrase (IN) by an LEDGF/p75-derived peptide modified with an N-terminal succinimide group. The covalent inhibition is mediated by direct binding of the succinimide to the amine group of a lysine residue in IN. The peptide serves as a specific recognition sequence for the target protein, while the succinimide serves as the binding moiety. The combination of a readily synthesizable peptide precursor with easy and efficient binding to the target protein makes this approach a promising new strategy for designing lead compounds.

Keywords: HIV-1 integrase; covalent inhibitors; peptides; succinimide.

MeSH terms

  • Dose-Response Relationship, Drug
  • HIV Integrase / metabolism*
  • HIV Integrase Inhibitors / chemical synthesis
  • HIV Integrase Inhibitors / chemistry
  • HIV Integrase Inhibitors / pharmacology*
  • Humans
  • Models, Molecular
  • Molecular Structure
  • Peptides / chemical synthesis
  • Peptides / chemistry
  • Peptides / pharmacology*
  • Structure-Activity Relationship
  • Succinimides / chemical synthesis
  • Succinimides / chemistry
  • Succinimides / pharmacology*

Substances

  • HIV Integrase Inhibitors
  • Peptides
  • Succinimides
  • succinimide
  • HIV Integrase
  • p31 integrase protein, Human immunodeficiency virus 1